Internal Medicine, Medical Oncology · San Francisco, CA
NPI
1861482853
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2100 Webster St, Suite 326
San Francisco, CA, 94115
Phone (415) 885-8600
Groups this clinician bills Medicare through
Medicare paid, 2024
$899K
47,372 services
Medicare patients, 2024
136
Average age 74
Drug cost, 2024
$3.4M
870 prescriptions
Company payments, 2025
$2,029
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wei Wang was code J0897 (injection, denosumab, 1 mg), 5,340 times for 17 patients. In total Wei Wang billed 47,372 services in 58 codes, and Medicare paid $899K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,340 | 17 | $20.04 | $107K |
| 85025 Blood Count | Office | 200 | 39 | $7.61 | $1,522 |
| 36415 Venipuncture Blood Collection | Office | 181 | 42 | $5.88 | $1,064 |
| 99214 Office E&M - Established | Office | 175 | 77 | $105.81 | $19K |
| 99213 Office E&M - Established | Office | 154 | 86 | $72.18 | $11K |
| 96413 Chemotherapy Administration | Office | 131 | 16 | $139.05 | $18K |
| 96372 Injection Administration | Office | 82 | 22 | $14.16 | $1,161 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 70 | 14 | $4.69 | $328 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 53 | 11 | $0.51 | $26.86 |
| 99215 Office E&M - Established | Office | 39 | 19 | $159.29 | $6,212 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 28 | 18 | $29.30 | $820 |
| 99205 Office E&M - New | Office | 21 | 21 | $205.95 | $4,325 |
| 96365 Intravenous Infusion, Hydration | Office | 16 | 14 | $62.48 | $1,000 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 11 | 11 | $14.79 | $163 |
By year: 2022 $924K for 55,474 services; 2023 $795K for 39,543 services; 2024 $899K for 47,372 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 200 | 39 | $7.61 | $1,522 |
| 36415 Venipuncture Blood Collection | 181 | 42 | $5.88 | $1,064 |
Medicare prescription drug claims, 2024
In 2024, the drug Wei Wang prescribed most often to Medicare patients was Anastrozole, with 306 prescriptions and refills. In total Wei Wang wrote 870 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 306 | 802 | 79 | $6,818 |
| Tagrisso Osimertinib Mesylate | 97 | 97 | Under 11 | $1.5M |
| Tamoxifen Citrate Generic | 73 | 215 | 22 | $1,259 |
| Trazimera Trastuzumab-Qyyp | 61 | 61 | Under 11 | $220K |
| Omeprazole Generic | 26 | 45 | Under 11 | $97.62 |
| Letrozole Generic | 22 | 60 | Under 11 | $551 |
| Pantoprazole Sodium Generic | 15 | 23 | Under 11 | $169 |
| Exemestane Generic | 14 | 28 | Under 11 | $1,551 |
| Jakafi Ruxolitinib Phosphate | 13 | 13 | Under 11 | $217K |
| Imbruvica Ibrutinib | 12 | 12 | Under 11 | $173K |
| Calquence Acalabrutinib Maleate | 12 | 12 | Under 11 | $174K |
| Kisqali Ribociclib Succinate | 12 | 12 | Under 11 | $188K |
| Abiraterone Acetate Generic | 12 | 12 | Under 11 | $60K |
| Eligard Leuprolide Acetate | 12 | 34 | Under 11 | $13K |
| Fulvestrant Generic | 12 | 12 | Under 11 | $11K |
Brand drugs: 292 claims; generic drugs: 578 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wei Wang $2,029 ($2,029 in general payments such as food, travel and fees) from 24 companies. The largest payer was Novartis Pharmaceuticals Corporation with $360.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 12 | $360 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $210 |
| Merck Sharp & Dohme LLC MRK | 6 | $183 |
| Pfizer Inc. PFE | 6 | $180 |
| Array Biopharma Inc PFE | 6 | $179 |
| Daiichi Sankyo Inc. 4568.T | 6 | $139 |
| Eisai Inc. 4523.T | 3 | $80 |
| Abbvie Inc. ABBV | 3 | $73.2 |
| Sobi, Inc SOBI.ST | 3 | $73.08 |
| Coherus Oncology, Inc. CHRS | 2 | $68.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.